Säälik P, Lingasamy P, Toome K, Mastandrea I, Rousso-Noori L, Tobi A, Simón-Gracia L, Hunt H, Paiste P, Kotamraju VR, Bergers G, Asser T, Rätsep T, Ruoslahti E, Bjerkvig R, Friedmann-Morvinski D, Teesalu T.
J Control Release. 2019 Jun 27. pii: S0168-3659(19)30328-1. doi: 10.1016/j.jconrel.2019.06.018. [Epub ahead of print].

Karolczak-Bayatti M, Forbes K, Horn J, Teesalu T, Harris LK, Westwood M, Aplin JD.
Nanoscale. 2019 Jun 27;11(25):12285-12295. doi: 10.1039/c8nr10337b.

Asciutto EK, Kopanchuk S, Lepland A, Simón-Gracia L, Aleman C, Teesalu T, Scodeller P
J Phys Chem B, 2019 Mar 7;123(9):1973-1982. doi: 10.1021/acs.jpcb.8b11876. Epub 2019 Feb 27.

Hussain S, Joo J, Kang J, Kim B, Braun GB, She ZG, Kim D, Mann AP, Mölder T, Teesalu T, Carnazza S, Guglielmino S, Sailor MJ, Ruoslahti E..
Nat Biomed Eng. 2018 Feb;2(2):95-103. doi: 10.1038/s41551-017-0187-5. Epub 2018 Jan 22.

Prof. Tambet Teesalu gave an inaugural lecture entitled “Nanomedicine: big opportunities in a small world” in the main hall of the University of Tartu on 14.05.2019.

This establishment of a professorship in nanomedicine at the University of Tartu underlines the importance that the University attributes to this exponentially growing interdisciplinary field of medicine.

https://www.ut.ee/et/uritused/nanomeditsiini-prof-tambet-teesalu-inauguratsiooniloeng-nanomeditsiin-suured-voimalused

Hedi Hunt successfully defended her Ph.D. thesis "Precision targeting of intraperitoneal tumors with peptide-guided nanocarriers" on April 18th, 2019. Her thesis dealt with the development of peptide-guided nanoparticles for therapy and imaging of peritoneal carcinomatosis. We wish Hedi good luck in her future career!

http://researchinestonia.eu/2019/04/19/smart-nanoparticles-help-improve-treatment-of-peritoneal-tumors/

https://www.ut.ee/et/uritused/hedi-hunt-precision-targeting-intraperitoneal-tumors-peptide-guided-nanocarriers

http://dspace.ut.ee/handle/10062/63502

Image: Hedi Hunt and her opponent Professor Pirjo Laakkonen PhD of the University of Helsinki (Finland) during the thesis discussion.

We look for talented M.Sc. and PhD candidates (molecular medicine, cancer biology, drug delivery, nanomedicine) to join our lab in fall 2019.

Apply now: This email address is being protected from spambots. You need JavaScript enabled to view it.

 

For more information Click Here

Tuesday, 16 October 2018 10:51

Peptide targeted polymersomes bind to M2 human macrophages

Polymersomes targeted with an M2 macrophage binding peptide (green) identified in our lab using phage display bind to and are taken up by M2s (red) originated from human primary monocytes. Scale bar 10µm. Authors: Anni Lepland, Pablo Scodeller, Lorena Simon Gracia

Dr. Teesalu has given a series of invited talks on international conferences in Europe and in the US: The 4th Brain Tumors Conference 2018: From Biology to Therapy ( June 21-23, 2018, Warsaw, Poland), Frontiers in Delivery of Therapeutics (August 21-23 2018, Tartu, Estonia), 11th European and Global Summit for Clinical Nanomedicine, Targeted Delivery and Precision Medicine, „The Building Blocks to Personalized Medicine“ (September 2 ‐ 5, 2018, Basel Switzerland), Boulder Peptide Symposium (September 24-27, 2018, Boulder, USA), workshop on self assembly and hierarchical materials in biomedicine: drug delivery, tissue engineering, sensing and safety (October 8 – 10, 2018, San Sebastián, Spain). The mission of the talks was to increase the awareness of nanomedicine and drug delivery community on the tumor homing peptides developed at our laboratory and establish new collaborations.

Dr. Teesalu (left) with Dr. Sergio Moya (the organizer of the workshop on self assembly and hierarchical materials in biomedicine in San Sebastián, Spain

Monday, 10 September 2018 10:27

Polymersomes targeted with an M2 macrophage binding peptide in a mouse model of triple negative breast cancer

Polymersomes targeted with an M2 macrophage binding peptide (green) identified in our lab using phage display home to M2 TAMs (red) after intravenous administration in a mouse model of triple negative breast cancer. Scale bar 20µm. Authors: Anni Lepland, Pablo Scodeller, Lorena Simon Gracia

Page 8 of 22